Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Study Purpose

The goal of this clinical study is to test how edecesertib (formerly known as GS-5718) can be useful in treating Cutaneous Lupus Erythematosus (CLE) in participants with CLE. Information on what is happening in the body relating to CLE, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Key

Inclusion Criteria:

  • - Either fulfill European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE) and/or have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time.
  • - Must have active CLE at screening and Day 1.
Individuals with acute CLE (ACLE) must have involvement of 2 distinct body areas.
  • - Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A) score (excluding alopecia) of ≥ 8 and CLASI-A erythema score of ≥ 4 during screening and on Day 1.
Individuals with SLE must have Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of ≥ 4 at screening.
  • - Presence of at least 1 representative lupus skin lesion amenable to punch biopsy and individual willingness to undergo skin punch biopsy at 2 time points.
  • - Must have documented prior intolerance or inadequate response at any time (per investigator judgement) to protocol-specified treatments.
  • - Topical corticosteroids or topical calcineurin inhibitors.
  • - Oral corticosteroids.
  • - Any other nonbiologic standard-of-care therapy, including, but not limited to: chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil (MMF), leflunomide, dapsone, or methotrexate (MTX).
  • - Individuals willing to comply with all study visits and assessments.
Key

Exclusion Criteria:

  • - Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or localized acute CLE involving only 1 distinct body area at screening and Day 1.
  • - Have highly active SLE (including but not limited to lupus nephritis, neuropsychiatric SLE, and/or vasculitis).
  • - Presence of active skin conditions other than cutaneous lupus that may interfere with assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus).
  • - Meet protocol-specified infection or lab criteria.
  • - Any active infection that is clinically significant (per investigator judgment).
  • - Any history of clinically significant liver disease.
  • - Significant cardiovascular disease.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05629208
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Gilead Sciences
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Gilead Study Director
Principal Investigator Affiliation Gilead Sciences
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Czechia, Germany, Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cutaneous Lupus Erythematosus (CLE)
Study Website: View Trial Website
Arms & Interventions

Arms

Experimental: Edecesertib

Participants will receive edecesertib 30 mg, once daily starting on Day 1 for up to 12 weeks.

Placebo Comparator: Edecesertib Placebo

Participants will receive edecesertib placebo, once daily starting on Day 1 for up to 12 weeks.

Interventions

Drug: - Edecesertib

Tablets administered orally

Drug: - Edecesertib Placebo

Tablets administered orally

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Fremont, California

Status

Recruiting

Address

Center for Dermatology Clinical Research Inc.

Fremont, California, 94538

UCSD Perlman Medical Offices, La Jolla, California

Status

Recruiting

Address

UCSD Perlman Medical Offices

La Jolla, California, 92037

Inland Rheumatology Clinical Trials Inc., Upland, California

Status

Recruiting

Address

Inland Rheumatology Clinical Trials Inc.

Upland, California, 91786

Aurora, Colorado

Status

Recruiting

Address

University of Colorado, Barbara Davis Center, Center for Clinical Research

Aurora, Colorado, 80045

New Haven, Connecticut

Status

Recruiting

Address

Yale Center for Clinical Investigation (YCCI)

New Haven, Connecticut, 06510

Clinical Research of West Florida, Inc., Clearwater, Florida

Status

Recruiting

Address

Clinical Research of West Florida, Inc.

Clearwater, Florida, 33765

Reliant Medical Research, Miami, Florida

Status

Recruiting

Address

Reliant Medical Research

Miami, Florida, 33165

HMD Research LLC, Orlando, Florida

Status

Recruiting

Address

HMD Research LLC

Orlando, Florida, 32819

Emory University School of Medicine, Atlanta, Georgia

Status

Recruiting

Address

Emory University School of Medicine

Atlanta, Georgia, 30303

Indianapolis, Indiana

Status

Recruiting

Address

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, 46250

New York, New York

Status

Recruiting

Address

Columbia University Medical Center- Herbert Irving Pavilion

New York, New York, 10032

OnSite Clinical Solutions, LLC, Charlotte, North Carolina

Status

Recruiting

Address

OnSite Clinical Solutions, LLC

Charlotte, North Carolina, 28204

Middleburg Heights, Ohio

Status

Recruiting

Address

Paramount Medical Research & Consulting, LLC

Middleburg Heights, Ohio, 44130

Philadelphia, Pennsylvania

Status

Recruiting

Address

Dept. of Dermatology, Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM)

Philadelphia, Pennsylvania, 19104

Vanderbilt University Medical Center, Nashville, Tennessee

Status

Recruiting

Address

Vanderbilt University Medical Center

Nashville, Tennessee, 37232

Metroplex Clinical Research Center, Dallas, Texas

Status

Withdrawn

Address

Metroplex Clinical Research Center

Dallas, Texas, 75231

Gulf Bank Medical Center, Houston, Texas

Status

Recruiting

Address

Gulf Bank Medical Center

Houston, Texas, 77037

Epic Medical Research - Red Oak, Red Oak, Texas

Status

Recruiting

Address

Epic Medical Research - Red Oak

Red Oak, Texas, 75154

Sun Research Institute, San Antonio, Texas

Status

Recruiting

Address

Sun Research Institute

San Antonio, Texas, 78215

International Sites

Praha 2, Czechia

Status

Recruiting

Address

Všeobecná fakultní nemocnice v Praze, Dermatovenerologická klinika

Praha 2, , 128 08

Kožní ambulance Fialová, s.r.o., Praha, Czechia

Status

Recruiting

Address

Kožní ambulance Fialová, s.r.o.

Praha, , 100 34

Berlin, Germany

Status

Recruiting

Address

Charité - Universitätsmedizin Berlin Klinik für Dermatologie, Allergologie und Venerologie Allergie Centrum

Berlin, ,

Dresden, Germany

Status

Recruiting

Address

Universitätsklinikum Carl Gustav Carus Klinik und Poliklinik für Dermatologie

Dresden, , 01307

Freiburg, Germany

Status

Recruiting

Address

Universitatsklinikum Freiburg Klinik fur Dermatologie und Venerologie

Freiburg, , 79104

Leipzig, Germany

Status

Recruiting

Address

Universitätsklinikum Leipzig AöR Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie Klinische Forschungseinheit (KFE) - Haus 10

Leipzig, , 04103

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Status

Recruiting

Address

Hospital de la Santa Creu i Sant Pau

Barcelona, , 8023

Hospital General de Granollers, Granollers, Spain

Status

Recruiting

Address

Hospital General de Granollers

Granollers, , 08402

Hospital Universitario Infanta Leonor, Madrid, Spain

Status

Recruiting

Address

Hospital Universitario Infanta Leonor

Madrid, , 28031

Hospital Universitario de Navarra, Pamplona, Spain

Status

Recruiting

Address

Hospital Universitario de Navarra

Pamplona, , 31008